MétaCan
Menu
← Back to cohort
Record W2792256775 · doi:10.1093/ecco-jcc/jjx180.803

P676 Correlation of lipid levels with reduction in inflammation in patients with ulcerative colitis: Data from the tofacitinib OCTAVE clinical trials

2018· article· en· W2792256775 on OpenAlexaff
Brian G. Feagan, Christina Ha, Pam R. Taub, D. Quirk, Chudy I. Nduaka, Leonardo Salese, Geoffrey Chan, Gary S. Friedman, W Wang, Chunyan Su, Walter Reinisch

Bibliographic record

VenueJournal of Crohn s and Colitis · 2018
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsRobarts Clinical TrialsWestern University
Fundersnot available
KeywordsTofacitinibUlcerative colitisMedicinePlaceboInternal medicineGastroenterologyLipid profileJanus kinase inhibitorCholesterolRheumatoid arthritisDiseasePathology

Abstract

fetched live from OpenAlex

Tofacitinib is an oral, small molecule Janus kinase inhibitor that is being investigated for ulcerative colitis (UC). Mild lipid elevations—with no evidence suggesting correlation with major cardiovascular events—have been seen in tofacitinib-treated patients (patients).1,2 We evaluated relationships between inflammatory status and lipid levels in tofacitinib-treated patients with UC. This analysis included patients from two randomised, placebo-controlled tofacitinib induction trials in patients with moderate-to-severe UC (OCTAVE Induction 1 and 2, NCT01465763 and NCT01458951). Correlation of Week 8 changes from baseline in lipid parameters (low- and high-density lipoprotein cholesterol [LDL; HDL], and total cholesterol [TC]) with Week 8 changes from baseline in C-reactive protein (CRP), and with the proportions of patients with mucosal healing (Mayo endoscopic subscore ≤1) and remission (total Mayo score ≤2, no individual subscore >1 and rectal bleeding subscore = 0) at Week 8, were determined. In OCTAVE Induction 1 and 2, 234 patients received placebo and 905 received tofacitinib 10 mg twice daily (BID). Consistent with previously reported data,2 there were greater increases from baseline in lipid levels, decreases from baseline in CRP, and greater rates of mucosal healing and remission at Week 8 with tofacitinib 10 mg BID vs. placebo (Table). The Pearson correlation coefficients at Week 8 between CRP and LDL, HDL and TC levels were significantly different from zero for both placebo-treated (LDL: −0.23; HDL: −0.34; TC: −0.36) and tofacitinib-treated patients (LDL: −0.19; HDL: −0.25; TC: −0.27). For tofacitinib-treated patients, correlation coefficients at Week 8 between mucosal healing and HDL (0.12) and TC (0.09), and between remission and HDL (0.08), were significantly different from zero. There was significant negative but small correlation between lipid and CRP changes in the tofacitinib and placebo groups. These data suggest that lipid changes seen in patients treated with tofacitinib may be partially due to the beneficial effect of reduced inflammation. More studies are warranted to better understand these correlations. 1. Charles-Schoeman C et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum, 2016;46:261–71. 2. Sandborn WJ, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2017;376:1723–36.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.008
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.025

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.008
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.044
GPT teacher head0.327
Teacher spread0.284 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and Colitis→Same topicInflammatory Bowel Disease→French-language works237,207→